Key result
Using the Bayer ACS:180 troponin I assay at a 0.1 microg/L cut-off led to inconsistent risk group assignment in 8% of cases on repeat analysis due to assay imprecision.
Why the study?
Is the Bayer ACS:180 troponin I assay reliable for risk stratification at a cut-off of 0.1 microg/L?
Population
4850 routine samples for troponin I measurement
Design
Other
Authors
Loading...
Assay imprecision at low cut-offs warrants caution in MI diagnosis; leaves open reliable 99th-centile use pending precision improvements.
Observational (n=4,850)
Is the Bayer ACS:180 troponin I assay reliable for risk stratification at a cut-off of 0.1 microg/L?
The Bayer ACS:180 troponin I assay has significant imprecision at the 0.1 microg/L cut-off, potentially leading to inconsistent risk assessment in NSTEMI patients.
Sheehan et al. (2002) conducted an observational in non-ST-elevation myocardial infarction (n=4,850). Bayer ACS:180 troponin I assay was evaluated on Assignment to a different risk group on repeat analysis due to assay imprecision at 0.1 microg/L. Using the Bayer ACS:180 troponin I assay at a 0.1 microg/L cut-off led to inconsistent risk group assignment in 8% of cases on repeat analysis due to assay imprecision.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: